A new stroke within 90 days (primary efficacy outcome) occurred in 222 patients (7.3%) in the clopidogrel–aspirin group and in 279 patients (9.2%) in the aspirin group (marginal estimated hazard ...

Because aspirin can contribute to the danger of big bleeds like aneurysms, researchers wanted to know whether it might also be a factor in more subtle blood loss: the kind that may lead to anemia ...

In a large, long-term trial, cilostazol was as effective as aspirin at preventing recurrent stroke and was associated with fewer hemorrhages. Antiplatelet drugs have an established role in ...

SAN FRANCISCO — In patients with ACS, stopping aspirin for ticagrelor monotherapy within 1 month of receiving a drug-eluting stent did not increase adverse CV and bleeding events compared with ...

Trial medication was discontinued for other reasons in 687 patients (34.1%) in the apixaban group and 697 patients (34.9%) in the aspirin group.

By the median follow-up of 33.8 months, 253 IDFS events had been recorded, with slightly more events in the aspirin group than in the placebo group, but without statistical significance.

(This study used low-dose aspirin -- 100 mg -- rather than the full-dose of 325 mg that you are taking.) The risk of bleeding was about the same among the aspirin group and the Xarelto group.

Effect of Low-Dose Aspirin Versus Placebo on Incidence of Anemia in the Elderly. Annals of Internal Medicine, 2023; DOI: 10.7326/M23-0675 ...